New strategies for the treatment of hyperkalemia
European Journal of Internal Medicine · 2025-02 · 132 · 18-26
DOI: 10.1016/j.ejim.2024.10.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2025-02. Verfasst von Stefano Masi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefano.masi@unipi.it. Hauptthemen laut MEDLINE: Hyperkalemia, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Renin-angiotensin-aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are key drugs in the management of patients with cardiovascular diseases (CVD), particularly those with hypertension, diabetes, chronic kidney disease and heart failure (HF), given their demonstrated effectiveness in reducing the risk of both surrogate and hard endpoints. Despite their positive impact on the outcome, patients with RAASi and MRAs are particularly vulnerable to hyperkalaemia, with approximately 50 % of these individuals experiencing two or more recurrences annually. The common practice of reducing the dose or discontinuing the treatment with RAASi and MRAs in conditions of hyperkalaemia results in suboptimal management of these patients, with a potential impact on their mortality and morbidity risk. Recent guidelines from cardiovascular and renal international societies increasingly recognize the need for alternative strategies to manage the risk of hyperkalaemia, allowing the continuation of RAASi and MRA therapies. In this review, we summarise the new potential options available to manage hyperkalaemia in patients with CVD and the recommendations of the most recent guidelines on the topic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefano.masi@unipi.it.
- Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Italy.
- Hypertension and Cardiovascular Disease Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Italy.
- Hypertension and Cardiovascular Disease Research Center, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Italy; Cardiovascular Medicine Unit, Heart-Chest-Vascular Department, IRCCS…
Zitieren
APA
Masi, S., Dalpiaz, H., Piludu, S., Piani, F., Fiorini, G., & Borghi, C. (2025). New strategies for the treatment of hyperkalemia. European Journal of Internal Medicine, 132, 18-26. https://doi.org/10.1016/j.ejim.2024.10.016
Vancouver
Masi S, Dalpiaz H, Piludu S, Piani F, Fiorini G, Borghi C. New strategies for the treatment of hyperkalemia. European Journal of Internal Medicine. 2025;132:18-26. doi:10.1016/j.ejim.2024.10.016
BibTeX
@article{Masi2025,
author = {Masi, Stefano and Dalpiaz, Herman and Piludu, Sara and Piani, Federica and Fiorini, Giulia and Borghi, Claudio},
title = {New strategies for the treatment of hyperkalemia},
journal = {European Journal of Internal Medicine},
year = {2025},
volume = {132},
pages = {18--26},
doi = {10.1016/j.ejim.2024.10.016}
}
EUVIMED